Clinical Trial: A First Time In Human Study To Assess The Compound GSK615915

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915 in Healthy Volunteers and Mild Asthmatics.

Brief Summary: GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.

Detailed Summary:
Sponsor: GlaxoSmithKline

Current Primary Outcome: Side effects Lung function Blood tests Heart rate and blood pressure Heart monitored (ECG)

Original Primary Outcome: Same as current

Current Secondary Outcome: Levels of GSK615915A and any breakdown products in the blood and urine.

Original Secondary Outcome: Same as current

Information By: GlaxoSmithKline

Dates:
Date Received: November 15, 2006
Date Started: November 2005
Date Completion:
Last Updated: May 31, 2012
Last Verified: February 2011